Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies

E. P. Alessandrino, P. Bernasconi, A. Colombo, D. Caldera, G. Martinelli, P. Vitulo, L. Malcovati, C. Nascimbene, M. Varettoni, E. Volpini, C. Klersy, C. Bernasconi

Research output: Contribution to journalArticlepeer-review

Abstract

Sixty-five patients with hematological malignancies (25 multiple myeloma, 18 Hodgkin's disease, 22 non-Hodgkin's lymphomas) who received a carmustine-based regimen followed by autologous PBPC transplantation, were studied retrospectively to evaluate the incidence of post-transplant non-infective pulmonary complications (NIPCs), risk factors predictive of NIPCs, and response to steroids. Carmustine (BCNU) given i.v. at a dose of 600 mg/m2 was combined with etoposide and cyclophosphamide in 40 patients (BCV regimen) and with etoposide and melphalan in 25 patients (BEM regimen). Seventeen of 65 patients (26%) had one episode of NIPCs. The median time to NIPCs was 90 days (52-289). Factors that increased the risk of developing NIPCs on multivariate analysis were female sex (P <0.001) and BCV regimen (P <0.05). All patients with NIPCs received prednisone at a dose of 1 mg/kg body weight for 10 days then tapered by 5 mg every two days; complete response to steroids was achieved in 15 of 17 patients; one unresponsive patient died of interstitial pneumonia, BCNU given at the dose of 600 mg/m2 is well tolerated when associated with melphalan and etoposide. In females and in patients receiving BCNU with cyclophosphamide, a BCNU dose reduction may be advisable.

Original languageEnglish
Pages (from-to)309-313
Number of pages5
JournalBone Marrow Transplantation
Volume25
Issue number3
Publication statusPublished - 2000

Keywords

  • Autologous peripheral blood progenitor cell transplantation
  • Carmustine
  • Pulmonary toxicity

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies'. Together they form a unique fingerprint.

Cite this